Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
A ctDNA testing method has the capability to predict cancer recurrence, which could help guide therapy selections and uncover new drug development opportunities.
A ctDNA testing method has the capability to predict cancer recurrence, which could help guide therapy selections and uncover new drug development opportunities.
Progressive telomere shortening during successive cell divisions is thought to contribute to phase transition in chronic myeloid leukemia.
Researchers are promoting physician and patient awareness about the potential tie between depression and certain therapies.
Experimental research may provide a blue print for the treatment of many types of cancer.
Though early-stage bladder cancer is infrequently fatal, the decrease in recurrence rates has a meaningful impact on the quality of life for patients as well as treatment costs.
A new test has been shown to be capable of identifying eight different cancers by assessing levels of circulating proteins along with mutations in cell-free DNA.
Telomerase plays a crucial role in tumor proliferation, and a better understanding of its structure will pave the way for new drug development.
While a recent discovery of a series of communicable cancers has raised concerns, there has been no sign of readily transmittable cancer in people that could spread through a population the way the ones found in other species do.
Researchers are hotly pursuing 2 distinct biological paths that show remarkable promise in the hunt for an effective anticancer vaccine.
Knowing that food increases the absorption of some therapies presents the possibility of easily — and significantly — lowering treatment costs.